CANCER GENETICS AND EPIGENETICS (CGE)

癌症遗传学和表观遗传学(CGE)计划的长期目标是致力于 与癌症生物学相关的基本细胞过程，并寻找机会将 由此产生的信息投入临床使用。为此，将追求以下具体目标：1.确定 产生基因组不稳定性并促进肿瘤发生的分子过程；2.探索 DNA和染色质的表观遗传修饰如何影响肿瘤的发生和发展；以及 3.阐明控制细胞分裂的潜在机制，并确定这些机制是如何 死于癌症。 CGE计划是HICCC的两个基础科学计划之一。在取代前者时 发育生物学和遗传学计划它已经进行了重组，以增加癌症的相关性，并且 新的CGE计划对癌症的高度关注反映在NCI资金增加了400%。这个 该计划通过促进CGE研究人员之间的互动以及与其他人的互动来追求其科学目标 HICCC成员，鼓励合作研究项目和联合赠款提案，并提供 CGE研究人员分享他们的最新发现并考虑他们的基础研究的临床价值的论坛 研究成果。潜在的临床应用包括环境毒素的识别和分析， 调整治疗方案以适应“辐射旁观者”效应，发展生物剂量学， 在诊断/预测性实验室分析(包括监测)中使用纳米流体盒(“生物芯片”) 治疗反应)，高通量筛选以识别调节恶性的小分子 这些分子的治疗效果的临床前测试。 CGE方案由来自11个部门的32名成员(HICCC的所有正式成员)组成， 哥伦比亚大学。该计划得到了几个合作努力的支持，包括最近的一个 续签，五年期520万美元(直接费用)方案项目赠款，来自NCI，题为“辐射旁观者” 效果：机制“(P.I.，Tom Hei)。赠款的最后一个预算年度(2006年7月1日至2007年6月30日)， CGE方案收到了总计1712万美元(直接费用)的癌症相关赠款支持，包括 369万美元(直接成本)的NCI资金，1295万美元(直接成本)的其他与癌症相关的同行审查资金， 以及48万美元(直接成本)，用于与癌症相关的非同行审查资金。与癌症相关的总人数 自上一次提交(即，2003年至今)以来，当前计划成员的出版物为330份， 方案间出版物占17.0%，方案内出版物占12.4%。

The long-term goal of the Cancer Genetics and Epigenetics (CGE) Program is to pursue basic research on fundamental cellular processes relevant to cancer biology and to seek opportunities for translating the resulting information into clinical use. To this end, the following Specific Goals will be pursued: 1. Identify the molecular processes by which genomic instability is generated and contributes to oncogenesis; 2. Explore how epigenetic modifications of DMA and chromatin influence tumor initiation and progression; and 3. Elucidate the mechanisms underlying control of cell division and ascertain how these mechanisms are abrogated in cancer. The CGE Program is one of the two Basic Science Programs of the HICCC. In replacing the former Developmental Biology & Genetics Program it has been restructured to increase cancer relevance, and the heightened cancer focus of the new CGE Program is reflected by a 400% increase in NCI funding. The Program pursues its scientific goals by promoting interactions among CGE investigators and with other HICCC members, encouraging collaborative research projects and joint grant proposals, and providing a forum in which CGE investigators share their latest discoveries and consider the clinical value of their basic research findings. Potential clinical applications include identification and analysis of environmental toxins, modified therapeutic regimens to accommodate "radiation bystander" effects, development of biodosimetry, use of nanofluidic cassettes ("biochips") in diagnostic/predictive laboratory assays (including monitoring therapeutic responses), high-throughput screening to identify small molecules that modulate malignant processes, and pre-clinical testing of these molecules for therapeutic effects. The CGE Program consists of 32 members (all full members of the HICCC) from eleven departments at Columbia University. The Program is supported by several collaborative efforts, including a recently renewed, five-year $5.2M (direct costs) program project grant from the NCI entitled "Radiation Bystander Effects: Mechanisms" (P.I., Tom Hei). For the last budget year of the grant (July 1, 2006 - June.30, 2007), the CGE Program received a total of $17.12M (direct costs) in cancer-relevant grant support, including $3.69M (direct costs) in NCI funding, $12.95M (direct costs) in other cancer-related peer-reviewed funding, and $0.48M (direct costs) in cancer-related non-peer-reviewed funding. The total number of cancer-related publications by the current Program members since the previous submission (i.e., 2003-present) was 330, with 17.0% inter-programmatic and 12.4% intra-programmatic publications.